Skip to main content
2025 ASCRS Annual Scientific Meeting Main banner
Final Program


Visit ASCRS U
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
CME
CME
Invitation/Ticketed Event
Invitation/Ticketed Event
Invited Lectureship
Invited Lectureship
Award Recipient
Award Recipient
Self-Assessment
Self-Assessment
Social
Social
Industry
Industry
Back

Session: ePoster: Basic and Translational Science 1 (Sun8)

EP202 - Development of a Fecal Biobank in the North-Northeast Regions of Brazil: Effects of Oral Fecal Microbiota Transplantation on Graft-Versus-Host Disease.

Sunday, May 11, 2025
8:16 AM – 8:21 AM PT
Location: Monitor 1, Sails Pavilion, Upper Level
All of the relevant financial relationships listed below have been mitigated.
Lara Burlamaqui Veras: This individual has no financial relationships with ineligible companies.
Image or Table (Do Not add text here):

Purpose/Background:

Introduction: Fecal microbiota transplantation (FMT) has shown to be a promising approach in several health conditions. Among them, graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation has gained prominence. Studies indicate that changes in the intestinal microbiota are related to the development of intestinal GVHD, suggesting that FMT may be a viable therapeutic alternative. Therefore, it is necessary to create a fecal bank, where samples can be analyzed and studied for this purpose.

Objectives: The main objective is to establish a fecal bank to investigate the impact of oral fecal microbiota transplantation on the treatment of GVHD after allogeneic hematopoietic stem cell transplantation.

Methods/Interventions:

Method: Healthy donors will be selected, excluding those with infectious diseases transmitted by blood or FMT, as well as conditions that increase the risk of transmission of multidrug-resistant organisms. These donors will undergo interviews and laboratory tests, including stool analyses. Fecal samples will be stored in a bank developed at the Pharmacology Laboratory of the Federal University of Ceará (UFC). Approximately 50g of fecal substrate will be diluted in sterile 0.9% saline solution, processed and stored for 6 to 8 hours. Cryopreservation plays a key role, as it preserves the clinical efficacy of FMT, prevents crystallization of the material and allows for on-demand treatments. Fecal capsules will be used due to their practicality, offering a less invasive route and with lower risks of complications associated with invasive procedures. A prospective interventional clinical trial will be conducted, involving twenty patients divided into two groups: one receiving conventional treatment for GVHD and the other receiving FMT. Both groups will be monitored for a period of two years.

Results/Outcomes:

Results: The implementation of a fecal bank makes it possible to provide high-quality samples, ready for immediate use, in addition to allowing monitoring of treatment responses, adverse effects and long-term impacts of FMT. FMT is expected to be safe and effective for patients, with a low incidence of adverse events, promoting the restoration of the intestinal microbiota and recovery of the gastrointestinal tract. In addition, a favorable and long-lasting clinical response is expected, with a reduction in GVHD recurrences.

Conclusion/Discussion:

Conclusion: The efficacy of FMT in the treatment of intestinal GVHD is enhanced when a well-structured and monitored fecal bank is available, providing more consistent and reproducible responses.